MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China and internationally. The company engages in research and development, manufacture, and sale of medical devices in the field of left atrial appendage, and treating valvular heart diseases, as well as properties management. It’s product portfolio includes transcatheter aortic valves, left atrial appendage closure, transcatheter mitral valves, transcatheter tricuspid valves, and surgical accessories, as well as procedural accessories; and VitaFlow, VitaFlow Liberty, VitaFlow Liberty Flex, Alwide Plus, AccuSniperTM, AnchorMan LAAC System, AnchorMan LAAA System, and various TAVI, TMV, TTV, and LAA products. In addition, the company provides technical consultation and technical services for medical devices clinical trial. MicroPort CardioFlow Medtech Corporation was founded in 2009 and is headquartered in Shanghai, China.
Metrics to compare | 2160 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2160PeersSector | |
---|---|---|---|---|
P/E Ratio | −57.2x | −28.3x | −0.5x | |
PEG Ratio | −0.64 | 0.10 | 0.00 | |
Price/Book | 1.3x | 2.6x | 2.6x | |
Price / LTM Sales | 7.8x | 8.0x | 3.3x | |
Upside (Analyst Target) | 38.2% | 3.4% | 43.3% | |
Fair Value Upside | Unlock | −10.1% | 6.9% | Unlock |